Novartis bets up to $900M for radioligand therapy from China’s BoomRay

Leave a Comment / By /

Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top